308 related articles for article (PubMed ID: 31340607)
1. The Future of Lipid-lowering Therapy.
Zwol WV; Rimbert A; Kuivenhoven JA
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31340607
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
4. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
[TBL] [Abstract][Full Text] [Related]
6. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
[TBL] [Abstract][Full Text] [Related]
7. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
Lupo MG; Ferri N
J Cardiovasc Dev Dis; 2018 Jul; 5(3):. PubMed ID: 30011918
[TBL] [Abstract][Full Text] [Related]
9. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
11. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
12. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward NC; Chan DC; Watts GF
BioDrugs; 2022 Mar; 36(2):121-135. PubMed ID: 35286660
[TBL] [Abstract][Full Text] [Related]
13. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
Malick WA; Goonewardena SN; Koenig W; Rosenson RS
J Am Coll Cardiol; 2023 Apr; 81(16):1633-1645. PubMed ID: 37076218
[TBL] [Abstract][Full Text] [Related]
16. [Effect of proprotein convertase subtilisin/kexin type 9 inhibitor on blood lipid profile in patients with extremely high risk atherosclerotic cardiovascular disease].
Wang J; Deng S; Liu Y; She Q; Du J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Mar; 32(3):341-344. PubMed ID: 32386000
[TBL] [Abstract][Full Text] [Related]
17. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
18. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
Kim JY; Kim NH
J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
[TBL] [Abstract][Full Text] [Related]
19. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
